| 三氧化二砷治疗急性早幼粒细胞白血病的进展 |
| |
| 引用本文： | 祝洪明,李军民. 三氧化二砷治疗急性早幼粒细胞白血病的进展[J]. 药学与临床研究, 2012, 20(4): 277-284 |
| |
| 作者姓名： | 祝洪明 李军民 |
| |
| 作者单位： | 上海交通大学医学院附属瑞金医院血液科,上海,200025 |
| |
| 摘 要： | 三氧化二砷(As2O3)用于治疗急性早幼粒细胞白血病(APL)已有20余年,通过特异性降解PML-RARα融合蛋白,As2O3在复发难治和初发APL患者中均获得了较理想的疗效,不良反应较轻,已成为复发难治APL的首选药物.通过进一步临床试验,As2O3有望成为初发APL的一线用药,并可减低甚至取代化疗,使部分APL成为无需化疗而获得治愈的血液学肿瘤.
|
| 关 键 词： | 三氧化二砷 急性早幼粒细胞白血病 疗效 不良反应 一线用药 |
| 收稿时间： | 2012-05-15 |
| 修稿时间： | 2012-06-26 |
Progress on the Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide |
| |
| ZHU Hong-ming and LI Jun-min. Progress on the Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide[J]. Pharmacertical and Clinical Research, 2012, 20(4): 277-284 |
| |
| Authors: | ZHU Hong-ming and LI Jun-min |
| |
| Affiliation: | Department of Hematology,Rui Jin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China |
| |
| Abstract: | Arsenic trioxide(As2O3) has been used to treat acute promyelocytic leukemia(APL) for over 20 years.It is of high efficacy and minimal adverse effect among both relapsed-refractory and newly diagnosed APL patients by specifically degrading the PML-RARα fusion protein,which makes it the first choice for relapsed and refractory APL.If confirmed by further clinical trials,As2O3 will become a promising front-line therapy for de novo APL,and it will reduce or substitute chemotherapy,thus turning some APL into curable hematologic malignancy without the involvement of chemotherapy. |
| |
| Keywords: | Arsenic trioxide Acute promyelocytic leukemia Efficacy Adverse effect Front-line therapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《药学与临床研究》浏览原始摘要信息 |
|
点击此处可从《药学与临床研究》下载全文 |
|
